Objective: To investigate the clinical manifestation, immunophenotypes and prognostic factors of patients with primary tonsil afftive large B cell lymphoma ( PT-DLBCL ).
Methods: The clinical data including clinical characterstics, typing, staging, treatment efficacy and prognostic factors of PT-DLBCL patients were collected and analyzed restrospectively.
Results: Out of 36 cases with the detinite cell origin, 24 cases (66.7%) were detecmined as the type of germinal center B-cell (GCB) and 12 cases (33.3%) was non-germinal center B-cell (non-GCB), 15 (40.5%) out of 37 cases were in Ann Arbor stage Ⅰ, and 22 (59.5%) in stage Ⅱ. With the median follow-up of 44 (10-101) months, 2 cases (5.4%) failed to be followed-up, after treatment for 6 (3-8) cycles 35 patients were evaluated. Among them 26 cases (74.3%) reached to complete remission (CR), 8 cases (22.9%) to partial remission ( PR ), and 1 (2.8%) to stable disease (SD). Both the 3 years and 5 years progression-free survival ( PFS ) were 82.5%, and both 3 and 5 years overall survival (OS) were 95.5%. 5 cases (13.5%) received radiotherapy. The patients aged＞60 ( P＜0.05 ) or aged＞70 (P＜0.05) had shorter PFS than younger patients. The patients with increased lactic dehydrogenase ( LDH ) level (P＜0.01) and without rituximab (R) (P＜0.05) in the treatment regimen had relatively short OS.
Conclusion: The patients sensitive to chemotherapy and/or radiotherapy have a good prognosis. Most of the patients can obtain long-term survival after treatment. The effect of combined immunotherapy are better than that of the simple chemotherapy.
题目: 原发扁桃体弥漫大B细胞淋巴瘤37例临床分析.
目的: 总结原发扁桃体弥漫大B细胞淋巴瘤（PT-DLBCL）的临床特征、免疫表型及预后因素.
方法: 收集2009年10月至2018年2月初诊的37例PT-DLBCL患者临床资料，包括临床特征、分型、分期、疗效及预后，并进行回顾性分析.
结果: 37例中男性22例（59.5%），女性15例（40.5%），中位年龄57（16-86）岁。能明确细胞起源的36例患者中，生发中心B细胞（GCB）型占66.7%，非生发中心B细胞（non-GCB）型占33.3%。Ann Arbor分期Ⅰ期占40.5 %，Ⅱ期占59.5%，无Ⅲ、Ⅳ期患者。中位随访时间44（10-101）月，2例患者（5.4%）失访。中位治疗6（3-8）个疗程后对35例患者进行评估。结果显示，26例（74.3%）达完全缓解（CR），8例（22.9%）达部分缓解（PR），1例（2.8%）患者疾病稳定（SD）。3年及5年无进展生存（PFS）均为82.5%，3年及5年总生存（OS）均为95.5%。5例（13.5%）患者接受了放疗。年龄>60岁（P＜0.05）或年龄＞70岁（P＜0.05）的患者PFS均较相对年轻患者短；LDH水平增高（P＜0.001）、治疗方案中未使用R（P＜0.05）的患者OS相对短.
结论: PT-DLBCL患者对放、化疗敏感，预后较好，大多数患者治疗后可获得长期生存，联合免疫化疗的效果优于单纯化疗.